Regional and ethnic differences among patients with he cardiac death in heart failure registry

European Heart Journal 37, 3141-3153

DOI: 10.1093/eurheartj/ehw331

Citation Report

#	Article	IF	CITATIONS
1	Prevention: some important steps forward, but many unmet needs in a world with cardiovascular disease as the leading cause of death. European Heart Journal, 2016, 37, 3179-3181.	1.0	17
2	Novel insights in HFrEF and HFpEF: patient characteristics, remote monitoring, and management. European Heart Journal, 2016, 37, 3117-3120.	1.0	O
3	Understanding the Epidemiology of Heart Failure to Improve Management Practices: An Asia-Pacific Perspective. Journal of Cardiac Failure, 2017, 23, 327-339.	0.7	72
4	Arrhythmias and sudden cardiac death: substrates, monitoring, and prevention. European Heart Journal, 2017, 38, 1693-1697.	1.0	O
5	Reverse J-Curve Relationship Between On-Treatment Blood Pressure and Mortality in Patients With Heart Failure. JACC: Heart Failure, 2017, 5, 810-819.	1.9	68
6	Disparity Between Indications for and Utilization of Implantable Cardioverter Defibrillators in Asian Patients With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	38
7	Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure. American Heart Journal, 2017, 191, 75-81.	1.2	31
8	Association of left ventricular ejection fraction with contrast-induced nephropathy and mortality following coronary angiography or intervention in patients with heart failure. Therapeutics and Clinical Risk Management, 2017, Volume 13, 887-895.	0.9	18
9	Clinical correlates and pharmacological management of Asian patients with concomitant diabetes mellitus and heart failure. Heart Failure Reviews, 2018, 23, 461-468.	1.7	4
10	Expanding the global borders of heart failure: the SHOP and PEOPLE studies. European Heart Journal, 2018, 39, 1781-1783.	1.0	4
11	Prevalence, clinical correlates, and outcomes of anaemia in multiâ€ethnic Asian patients with heart failure with reduced ejection fraction. ESC Heart Failure, 2018, 5, 570-578.	1.4	21
12	Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. European Heart Journal, 2018, 39, 1770-1780.	1.0	194
13	A single-center observational study on the efficacy of percutaneous coronary intervention for ischemic heart failure. Medicine (United States), 2018, 97, e0238.	0.4	1
14	Chronic obstructive pulmonary disease and βâ€blocker treatment in Asian patients with heart failure. ESC Heart Failure, 2018, 5, 297-305.	1.4	11
15	Management protocols for chronic heart failure in India. Indian Heart Journal, 2018, 70, 105-127.	0.2	27
16	2â€The challenges and triumphs of establishing a heart failure programme in singapore. , 2018, , .		O
17	3â€Experience of LVAD as destination therapy at ramathibodi hospital, bangkok. , 2018, , .		0
18	$1\hat{a}$ €Heart function replacement: the current state and a look into the future. , 2018, , .		O

#	Article	IF	CITATIONS
19	COMPARATIVE ANALYSIS OF HOSPITAL PHARMACOTHERAPY OF CHRONIC HEART FAILURE WITH REDUCED LEFT VENTRICULAR EJECTION FRACTIONS IN 2009-2010 AND 2014-2015. Rational Pharmacotherapy in Cardiology, 2018, 14, 21-26.	0.3	0
20	Red blood cell distribution width: A new prognostic marker of heart failure. Journal of Indian College of Cardiology, 2018, 8, 191-194.	0.1	0
21	Heart Failure With Preserved Ejection Fraction in the Young. Circulation, 2018, 138, 2763-2773.	1.6	52
22	Study of the Clinical Characteristics and Management of Indian Outpatients of Chronic Heart Failure with Coexistent Diabetes Versus those without Diabetes (HF-DIAB): Rationale and Design. Journal of Cardiovascular Diseases & Diagnosis, 2018, 06, .	0.0	0
23	Prevalence and short-term prognosis of heart failure: An in hospital prevalence study. Journal of Indian College of Cardiology, 2018, 8, 103-106.	0.1	1
24	Multiâ€ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HFâ€ACTION trial and the ASIANâ€HF registry. European Journal of Heart Failure, 2018, 20, 1281-1289.	2.9	23
25	Future biomarkers in cardiology: my favourites. European Heart Journal Supplements, 2018, 20, G37-G44.	0.0	25
26	Heart Failure in the Elderly. , 2018, , 437-452.		1
27	Effect of albumin-globulin score and albumin to globulin ratio on survival in patients with heart failure: a retrospective cohort study in China. BMJ Open, 2018, 8, e022960.	0.8	24
28	Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. The Lancet Global Health, 2018, 6, e1008-e1018.	2.9	113
29	Heart failure with preserved ejection fraction in Asia. European Journal of Heart Failure, 2019, 21, 23-36.	2.9	102
30	Heart failure around the world. European Journal of Heart Failure, 2019, 21, 1187-1196.	2.9	56
31	Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction. Korean Circulation Journal, 2019, 49, 469.	0.7	18
32	Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction. Diabetes Care, 2019, 42, 1792-1799.	4.3	52
33	The Dapagliflozin And Prevention of Adverseâ€outcomes in Heart Failure (DAPAâ€HF) trial: baseline characteristics. European Journal of Heart Failure, 2019, 21, 1402-1411.	2.9	159
34	Age-Related Characteristics and Outcomes of Patients With HeartÂFailure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 601-612.	1.2	97
35	Choosing a Career in Heart Failure. Circulation: Heart Failure, 2019, 12, e006026.	1.6	2
36	Clinical profile and one-year survival of patients with heart failure with reduced ejection fraction: The largest report from India. Indian Heart Journal, 2019, 71, 242-248.	0.2	16

#	Article	IF	CITATIONS
37	Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study. PLoS Medicine, 2019, 16, e1002916.	3.9	64
38	Effect of Diabetes Mellitus on Cardiac Resynchronization Therapy and to Prognosis in Heart Failure (from the Prospective Evaluation of Asian With Cardiac Resynchronization Therapy for Heart Failure) Tj ETQq1	1 <b>0.78</b> #31	' 4 rg¶T /Overlo
39	Outcomes and Effect of Treatment According to Etiology in HFrEF. JACC: Heart Failure, 2019, 7, 457-465.	1.9	94
40	Prescription patterns of antiâ€diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus. European Journal of Heart Failure, 2019, 21, 685-688.	2.9	5
41	Staphylococcal driveline infections are the predominant type of left ventricular assist device associated infections in Singapore. Infectious Diseases, 2019, 51, 417-424.	1.4	3
42	Association of Diabetic Retinopathy and Diabetic Kidney Disease With All-Cause and Cardiovascular Mortality in a Multiethnic Asian Population. JAMA Network Open, 2019, 2, e191540.	2.8	64
43	Physicians' guideline adherence is associated with longâ€term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. European Journal of Heart Failure, 2019, 21, 921-929.	2.9	86
44	Supporting the Management of Patients with Heart Failure within Asia-Pacific, Middle East, and African Countries: A Toolbox for Healthcare Providers. Cardiology, 2019, 142, 1-10.	0.6	4
45	The China Patient-centred Evaluative Assessment of Cardiac Events (PEACE) prospective heart failure study design. BMJ Open, 2019, 9, e025144.	0.8	26
46	Seipin Knockout Mice Develop HeartÂFailure With Preserved EjectionÂFraction. JACC Basic To Translational Science, 2019, 4, 924-937.	1.9	24
47	Cardiovascular issues in women: expanding diversity in medicine. European Heart Journal, 2019, 40, 3807-3811.	1.0	0
48	The role of N-terminal pro-B-type natriuretic peptide in prognostic evaluation of heart failure. Journal of the Chinese Medical Association, 2019, 82, 447-451.	0.6	9
49	Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. European Journal of Heart Failure, 2019, 21, 577-587.	2.9	38
50	Impact of diabetes and sex in heart failure with reduced ejection fraction patients from the ASIANâ€HF registry. European Journal of Heart Failure, 2019, 21, 297-307.	2.9	36
51	Defining a †frequent admitter†phenotype among patients with repeat heart failure admissions. European Journal of Heart Failure, 2019, 21, 311-318.	2.9	15
52	Coronary artery bypass graft versus percutaneous coronary intervention in acute heart failure. Heart, 2020, 106, 50-57.	1.2	11
53	Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure. JAMA Cardiology, 2020, 5, 401.	3.0	51
54	Potassium abnormalities in patients with heart failure from 11 Asian regions: insights from the ASIANâ€HF registry. European Journal of Heart Failure, 2020, 22, 751-754.	2.9	4

#	Article	IF	CITATIONS
55	Association between body surface area and prescribed doses of guidelineâ€directed medications among international patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 754-758.	2.9	4
56	Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIANâ€HF Registry. Journal of the American Heart Association, 2020, 9, e012199.	1.6	55
57	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age. Circulation, 2020, 141, 100-111.	1.6	145
58	Outcomes of Asian-Americans Implanted With Left Ventricular Assist Devices: AnÂInteragency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Analysis. Heart Lung and Circulation, 2020, 29, 1226-1233.	0.2	2
59	International Consortium for Health Outcomes Measurement (ICHOM): Standardized Patient-Centered OutcomesÂMeasurement Set for HeartÂFailure Patients. JACC: Heart Failure, 2020, 8, 212-222.	1.9	69
60	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: ⟨scp⟩GALACTICâ€HF⟨/scp⟩ baseline characteristics and comparison with contemporary clinical trials. European Journal of Heart Failure, 2020, 22, 2160-2171.	2.9	47
61	The Upcoming Epidemic of Heart Failure in South Asia. Circulation: Heart Failure, 2020, 13, e007218.	1.6	37
62	Patientâ€reported outcomes in heart failure with preserved vs. reduced ejection fraction: focus on physical independence. ESC Heart Failure, 2020, 7, 2051-2062.	1.4	9
63	Ethnic differences in atrial fibrillation among patients with heart failure in Asia. ESC Heart Failure, 2020, 7, 1419-1429.	1.4	6
64	Machine learning-based risk model using 123I-metaiodobenzylguanidine to differentially predict modes of cardiac death in heart failure. Journal of Nuclear Cardiology, 2022, 29, 190-201.	1.4	25
65	Effects of combined renin–angiotensin–aldosterone system inhibitor and betaâ€blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from <scp>BIOSTAT HF</scp> and <scp>ASIANâ€HF</scp> registries. European Journal of Heart Failure, 2020, 22, 1472-1482.	2.9	24
66	Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. The Lancet Global Health, 2020, 8, e411-e422.	2.9	104
67	Oleic Acid Attenuates Ang II (Angiotensin II)-Induced Cardiac Remodeling by Inhibiting FGF23 (Fibroblast) Tj ETQ	q0 0 0 rgE	BT /Overlock 1
68	An overview of hypertension and cardiac involvement in Asia: Focus on heart failure. Journal of Clinical Hypertension, 2020, 22, 423-430.	1.0	27
69	Sex and gender and cardiovascular medicine: impact in diabetes, acute coronary syndromes, and heart failure. European Heart Journal, 2020, 41, 1311-1314.	1.0	6
70	Predictors of mortality, strategies to reduce readmission, and economic impact of acute decompensated heart failure: Results of the Vellore Heart Failure Registry. Indian Heart Journal, 2020, 72, 20-26.	0.2	8
71	Prognostic Markers in Advanced Heart Failure. Journal of Evolution of Medical and Dental Sciences, 2021, 10, 39-44.	0.1	3
72	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Preventive Cardiology, 2022, 29, 275-300.	0.8	11

#	ARTICLE	IF	CITATIONS
73	Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study. Frontiers in Cardiovascular Medicine, 2020, 7, 602363.	1.1	14
74	Cost-effectiveness of a Telemonitoring Program for Patients With Heart Failure During the COVID-19 Pandemic in Hong Kong: Model Development and Data Analysis. Journal of Medical Internet Research, 2021, 23, e26516.	2.1	10
75	Extending the MADIT-ICD benefit score to heterogenous heart failure populations. European Heart Journal, 2021, 42, 4774-4775.	1.0	2
76	Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the ⟨scp⟩DAPAâ€HF⟨/scp⟩ trial. European Journal of Heart Failure, 2021, 23, 601-613.	2.9	33
77	Socioeconomic Status and Outcomes in Heart Failure With Reduced Ejection Fraction From Asia. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006962.	0.9	13
78	Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute HeartÂFailure. JACC: Heart Failure, 2021, 9, 349-359.	1.9	14
79	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 4442-4451.	1.0	38
80	Treatment with angiotensin receptor neprilysin inhibitor for Taiwan heart failure patients: Rationale and baseline characteristics of the TAROT-HF study. Journal of the Chinese Medical Association, 2021, 84, 833-841.	0.6	8
81	Costâ€utility analysis of addâ€on dapagliflozin in heart failure with reduced ejection fraction in the Philippines. ESC Heart Failure, 2021, 8, 5132-5141.	1.4	12
82	Efficacy of nurse-led cardiac rehabilitation on health care behaviours in adults with chronic heart failure: An experimental design. Clinical Epidemiology and Global Health, 2021, 12, 100859.	0.9	2
83	Ten-year survival and factors associated with increased mortality in patients admitted for acute decompensated heart failure in Thailand. Singapore Medical Journal, 2020, 61, 320-326.	0.3	5
84	Heart failure mortality compared between elderly and non-elderly Thai patients. Journal of Geriatric Cardiology, 2018, 15, 718-724.	0.2	7
85	Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. PLoS Medicine, 2018, 15, e1002541.	3.9	97
86	Influence of Race in the Association of Diabetes and Heart Failure. US Cardiology Review, 2018, 12, 17-21.	0.5	1
87	Efficacy of Cardiac Resynchronization Therapy Using Automated Dynamic Optimization and Left Ventricular-only Pacing. Journal of Korean Medical Science, 2019, 34, e187.	1.1	3
88	Readmissions, Death and Its Associated Predictors in Heart Failure With Preserved Versus Reduced Ejection Fraction. Journal of the American Heart Association, 2021, 10, e021414.	1.6	6
89	Hypertensive Heart Failure in Asia. Pulse, 2021, 9, 47-56.	0.9	5
90	Hospitalization for Heart Failure in the United States, UK, Taiwan, and Japan: An International Comparison of Administrative Health Records on 413,385 Individual Patients. Journal of Cardiac Failure, 2022, 28, 353-366.	0.7	11

#	Article	IF	CITATIONS
92	OBSOLETE: Heart Failure in the Elderly. , 2018, , .		0
93	Neurohumoral Pathway in Heart Failure. ACI (Acta Cardiologia Indonesiana), 2019, 5, 58.	0.0	0
96	A REVIEW ON GLOBAL TRENDS IN HEART FAILURE AND EVOLUTION OF ANGIOTENSIN–NEPRILYSIN INHIBITOR. Asian Journal of Pharmaceutical and Clinical Research, 0, , 32-37.	0.3	0
97	Implantable cardioverter defibrillators for sudden cardiac death prevention in China: A regional analysis from the improve SCA clinical trial. International Journal of Heart Rhythm, 2020, 5, 1.	0.0	0
98	The China Patient-centered Evaluative Assessment of Cardiac Events (China PEACE) retrospective heart failure study design. BMJ Open, 2018, 8, e020918.	0.8	5
99	Hierarchical management of chronic heart failure: a perspective based on the latent structure of comorbidities. ESC Heart Failure, 2021, , .	1.4	5
100	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Heart Failure, 2022, 24, 143-168.	2.9	41
101	Patient-level comparison of heart failure patients in clinical phenotype and prognosis from China and Sweden. BMC Cardiovascular Disorders, 2022, 22, 91.	0.7	3
102	Social Inequalities in Non-ischemic Cardiomyopathies. Frontiers in Cardiovascular Medicine, 2022, 9, 831918.	1.1	1
103	Effects of Dapagliflozin in Asian Patients With HeartÂFailure and Reduced Ejection Fraction in DAPA-HF. JACC Asia, 2022, , .	0.5	2
104	Frailty Among Asian Patients With HeartÂFailure. JACC Asia, 2021, 1, 314-316.	0.5	0
105	Prevalence and Prognostic Significance of Frailty in Asian Patients With HeartÂFailure. JACC Asia, 2021, 1, 303-313.	0.5	4
106	Global Benefit of SGLT2 Inhibitors in HeartÂFailure With Reduced EjectionÂFraction. JACC Asia, 2022, 2, 154-156.	0.5	0
107	The China Patient-centered Evaluative Assessment of Cardiac Events (China PEACE) retrospective heart failure study design. BMJ Open, 2018, 8, e020918.	0.8	8
108	Patient profiles on outcomes in patients hospitalized for heart failure: a 10â€year history of the Malaysian population. ESC Heart Failure, 2022, 9, 2664-2675.	1.4	5
109	Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects. JACC Asia, 2022, 2, 287-293.	0.5	6
110	Impact of 2016 American Society of Echocardiography/European Association of Cardiovascular Imaging Recommendations for the Evaluation of Left Ventricular Diastolic Function on Predicting Outcomes in Patients with Diabetes and Hypertension without a History of Cardiovascular Disease., 0, 1,.		0
111	Interaction of sex and diabetes in Asian patients with heart failure with mildly reduced left ventricular ejection fraction. Annals of the Academy of Medicine, Singapore, 2022, 51, 473-482.	0.2	3

#	Article	IF	CITATIONS
112	Evaluation of utilised doses of Heart Failure (HF) medications between genders and its association with clinical status among Heart Failure (HF) patients at hospital Serdang. International Journal of Health Sciences, 0, , 46797-46819.	0.0	0
113	Sex and ethnicity modified high 1-year mortality in patients in Singapore with newly diagnosed atrial fibrillation. Annals of the Academy of Medicine, Singapore, 2022, 51, 540-552.	0.2	2
114	Cause of Death Among Patients With Diabetes and HeartÂFailure With Reduced Ejection Fraction. JACC Asia, 2022, 2, 648-650.	0.5	1
115	Validity and Reliability of the Integrated Palliative Care Outcome Scale in Asian Heart Failure Patients. Palliative Medicine Reports, 2022, 3, 287-295.	0.4	2
116	Patient-Reported Versus Physician-Assessed Health Status in Heart Failure With Reduced and Preserved Ejection Fraction From ASIAN-HF Registry. Circulation: Cardiovascular Quality and Outcomes, 0, , .	0.9	0
117	Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause. Journal of the American Heart Association, 0, , .	1.6	1
118	Heart and Brain Failure. JACC Asia, 2023, , .	0.5	0
119	Incidence, Clinical Correlates, and Prognostic Impact of Dementia in HeartÂFailure. JACC Asia, 2023, 3, 108-119.	0.5	1
120	Public Perception of the Risk of Heart Disease and Their Willingness to Pay for Its Diagnosis in Malaysia., 2023, 2, 91-101.		0
121	Titration of medications and outcomes in multiâ€ethnic heart failure cohorts (with reduced ejection) Tj ETQq1 1	l 0.784314	rgBT /Overlo
122	Heart Failure and Multimorbidity in Asia. Current Heart Failure Reports, 2023, 20, 24-32.	1.3	3
123	Expert consensus on Ivabradine-based therapy for heart rate management in chronic coronary syndrome and heart failure with reduced ejection fraction in India. Current Cardiology Reviews, 2023, 19, .	0.6	0
125	Geographic differences in patients with acute myocardial infarction in the <scp>PARADISEâ€MI</scp> trial. European Journal of Heart Failure, 2023, 25, 1228-1242.	2.9	2
140	Management of Hypertension in the Asia-Pacific Region: A Structured Review. American Journal of Cardiovascular Drugs, 2024, 24, 141-170.	1.0	O